WEST PALM BEACH, FL AND LONDON, UK, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned for the third consecutive year as the Official Apparel and Jersey Partner of Chestertons Polo in the Park, bringing together world-class competition, sport-inspired fashion, thrilling entertainment, and memorable lifestyle experiences for one of London's most anticipated summer sporting events. Held June 5-7, 2026, at Hurlingham Park in central London, the three-day festival welcomed more than 30,000 attendees for a celebration of the sport of polo in one of the world's most iconic urban settings.The Red Sea Global Team Riyadh and the Disney+ Team Rivals fighting for the ball at Chestertons Polo in the ParkAs the Official Apparel and Jersey Partner, U.S. Polo Assn. outfitted all teams throughout the tournament with custom-designed performance jerseys while also providing staff uniforms and immersive brand experiences designed to connect consumers to the authentic roots of the brand and the sport of polo.Throughout the weekend, U.S. Polo Assn. created its largest presence yet at Chestertons Polo in the Park with a dedicated activation showcasing polo shirts and sport-inspired collections for men, women, and children, alongside an interactive photo wall and other fan experiences. Players distributed branded U.S. Polo Assn. caps to spectators directly from horseback after matches each day, creating memorable moments that brought fans closer to the action.For the first time, attendees also experienced "The Divot Stomp," U.S. Polo Assn.'s signature cocktail, offered exclusively in VIP hospitality areas and served during the event's iconic halftime tradition each day. The specialty drink, served in reusable aluminum cups with custom polo mallet stirrers, added another interactive element to the weekend celebration, with fans taking them home as keepsakes.The three-day polo festival also provided the perfect stage for U.S. Polo Assn.'s global polo shirt campaign, "An Icon Born from the Game," highlighting the authentic connection between the brand's most recognizable product and its origins in the sport of polo. Throughout the festival grounds, attendees experienced activations centered around the iconic polo shirt while exploring new seasonal collections inspired by sport and style."Chestertons Polo in the Park captures everything that makes the sport of polo special with competition, fashion, entertainment, accessibility, and community, all in the heart of one of the world's most vibrant cities," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar U.S. Polo Assn. brand. "As a brand born from the sport, our continued partnership allows us to connect with consumers in an authentic way while celebrating the heritage, energy, and global appeal that define both London and the sport of polo."Since launching in 2009, Chestertons Polo in the Park has evolved into one of the world's largest polo lifestyle festivals and remains the only polo tournament played in central London. The 2026 edition featured six teams representing global cities and brands at the event, including Disney+ Team Rivals, New Equity Team London, IBV Gold Team Cape Town, who's roster included U.S. Polo Assn. Brand Ambassadors Nico and Lucas Escobar, Kohn, Loeb & Co. Team Zurich, Icon Global/AMASE Team Texas, and the Red Sea Global Team Riyadh. The festival's daily themes include International Day on Friday, where Team England faced Team South Africa, followed by Ladies Day on Saturday and Finals and Family Day on Sunday.During the 2026 Chestertons Polo in the Park Final, the Red Sea Global Team Riyadh played against the Icon Global/AMASE Team Texas in a close game resulting in a 4-4 tie by the end of the final chukker. After an exciting run down, the Red Sea Global Team Riyadh took their third win in a row at Chestertons Polo in the Park, and teammate Cesar Crespo earned MVP."As the strategic partner for U.S. Polo Assn. in the United Kingdom, Chestertons Polo in the Park continues to be an important platform to showcase the authentic connection between our brand and the sport of polo," said Boo Jalil, CEO of Brand Machine Group, U.S. Polo Assn.'s licensing partner in the United Kingdom. "This event represents everything consumers love about U.S. Polo Assn., such as the heritage, style, accessibility, and fun, which allows us to engage directly with fans in one of our most important global markets."The United Kingdom remains a significant growth market for U.S. Polo Assn., which continues expanding retail distribution and consumer reach throughout the region. Consumers can explore the latest collections and sport-inspired styles at www.uspoloassn.co.uk."Chestertons Polo in the Park was created to make the sport of polo more accessible and bring new audiences closer to the game, and U.S. Polo Assn. continues to be an important part of that vision," said Rory Heron, Managing Director of Sportgate International and founding organizer of the event. "Their authentic connection to the sport, combined with engaging fan experiences and innovative activations, helps create the unique atmosphere that makes this event one of London's standout summer occasions."Beautiful guests posing at Chestertons Polo in the Park photo wallU.S. Polo Assn.'s merchandise tent at the three-day polo lifestyle festival, Chestertons Polo in the Park, in Downtown LondonPhoto Credit: Spot MeAbout U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, Star Sports in India, and BeIn Sports in the Middle East now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has recently been named one of USA Today's Most Trusted Brands and has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About Brand Machine Group (BMG)BMG is an international leader in fashion innovation which has established itself as a vertical manufacturer and global licensing specialist with over four decades of industry experience. Partnering with recognized market leaders, BMG manages a seamless and collaborative process of designing, manufacturing, and delivering quality products while championing the DNA of a diverse portfolio of brands, spanning fashion, sports, outdoor, and homeware including adult fashion, kidswear, and accessories.BMG's portfolio of brands includes U.S. Polo Assn. Penfield, New Balance Kids, Duchamp, Jack Wills, Flyers American Born, Lee Kids, Peckham Rye, Wrangler Kids, Juicy Couture, Franklin & Marshall, Elle Junior and Ben Sherman. BMG reaffirms its commitment to upholding sustainable and ethical business practices by ensuring full transparency throughout its global supply chain, aligning with the ETI Base Code.Visit brandmachinegroup.com and follow @brandmachinegroup. For appointments contact, sales@brandmachinegroup.comAbout Sportgate InternationalSportgate International is an international event management and sports marketing agency. Established in 2015, Sportgate International now owns events and consults with companies, luxury brands, world-class venues, tourism boards, and rights holders requiring sponsorship and event expertise. Sportgate International owns a portfolio of luxury events which encourages and enables the world's best brands, top companies, and individuals to further their corporate or personal objectives. The company also works with some of the most high-profile venues in the world, offering original content that enables networking and marketing to specific audiences.For more information, visit sportgateint.com.For Further Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comShannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ATLANTA, GA & SYDNEY, AU, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - Haven Safety AI, the AI-native platform for incident investigation and root cause analysis in high-risk operations, today announced the availability of its platform in Australia, marking the company's first international expansion.The launch brings Haven's safety intelligence platform to Australian organisations with capabilities designed for the country's distinct EHS, Work Health and Safety, data residency, and enterprise security requirements. Haven's knowledge graph has been localised to support Australian safety terminology, regulatory context, jurisdictional considerations, incident investigation workflows, and root cause analysis practices, enabling teams to conduct AI-assisted investigations with local operating context from the start.The Australian release also includes support for local data residency requirements and security controls designed for organisations managing sensitive operational, workforce, and safety information."Australia was the clear choice for Haven's first international market," said Joseph Hanna, Co-Founder and CEO of Haven Safety AI. "The country has a deep and serious safety culture, especially across high-risk industries, and a strong willingness to adopt innovation when it can improve how work is actually done. We built Haven's Australian availability around that reality: local WHS context, local data residency expectations, and the governance safety leaders need to use AI responsibly in incident investigation and RCA."Haven helps organisations move beyond digitised forms and static investigation templates by combining structured workflows, AI-assisted analysis, and a continuously learning knowledge graph. The platform supports safety teams through evidence collection, event reconstruction, causal analysis, corrective action development, investigation quality review, and enterprise-level learning across incidents.For Australian organisations, Haven's localised platform is designed to help teams:Conduct incident investigations and RCA with Australia-specific WHS and EHS contextImprove investigation consistency across sites, teams, and business unitsIdentify recurring causal patterns, failed controls, and emerging operational risksStrengthen corrective action quality and accountabilityMaintain governance, auditability, and security for sensitive safety dataSupport local data residency expectations for Australian operationsThe Australian launch comes as safety leaders increasingly evaluate AI as a core layer of the next generation of EHS technology."Our team evaluated Haven as part of a consulting engagement supporting a major Australian energy company in selecting and deploying AI-enabled investigation and learning capability. We were impressed," said Cam Stevens, Founder and CEO of Pocketknife Group. "Haven has been thoughtful about how AI and humans work together across the investigation and learning workflow. Their focus on helping organisations learn from incidents consistently and at scale is exactly where AI in workplace health and safety needs to go. We're excited to see Haven in the Australian market."Pocketknife Group is an Australia based consultancy that works with organisations navigating safety innovation, digital transformation, critical risk management, and the integration of AI and emerging technology into safety-critical systems."Haven's expansion into Australia is about more than making the product available in a new geography," Hanna added. "It is about building a platform that understands the local regulatory environment, respects local data requirements, and helps Australian safety teams turn every investigation into a stronger prevention system."Haven is available now for Australian enterprise customers across energy, utilities, infrastructure, construction, manufacturing, logistics, mining, and other high-risk sectors.For more information, visit www.havensafety.com.About HavenHaven Safety AI, a product of Haven Safety Corporation, provides an AI-native platform for incident investigations, root cause analysis, and proactive risk reduction. By combining artificial intelligence with a structured industry knowledge graph, Haven helps organizations capture frontline insights, analyze systemic causes, and continuously improve safety performance. For more information, visit www.havensafety.com.Media contact:Madeleine Moenchmadeleinem@accessnewswire.comSOURCE: Haven Safety Corporation Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛罗里达州西棕榈滩和英国伦敦, 2026年6月9日 - (亚太商讯 via SeaPRwire.com) - 作为美国马球协会（USPA）的官方运动品牌，U.S. Polo Assn. 连续第三年担任“切斯特顿公园马球赛”（Chestertons Polo in the Park）的官方服装及球衣合作伙伴，为这场伦敦最受期待的夏季体育盛事汇聚了世界级赛事、运动风尚、精彩纷呈的娱乐活动以及令人难忘的生活方式体验。这场为期三天的盛会于2026年6月5日至7日在伦敦市中心的赫林汉姆公园举行，吸引了超过30,000名观众，在世界上最具标志性的城市景观之一中共同庆祝马球运动的魅力。在切斯特顿“公园马球赛”上，红海全球队利雅得分队与迪士尼+队“劲敌”为争夺球权展开激烈角逐作为官方服装及球衣合作伙伴，U.S. Polo Assn. 为本届赛事的所有参赛队伍提供了定制高性能球衣，同时还提供了工作人员制服，并打造了沉浸式品牌体验，旨在让消费者深入了解该品牌及马球运动的纯正根源。整个周末，U.S. Polo Assn.在切斯特顿“公园马球赛”上打造了迄今为止规模最大的品牌展区，通过专属活动展示男女童马球衫及运动风系列，并设有互动拍照墙等粉丝体验区。每日比赛结束后，球员们直接在马背上向观众分发U.S. Polo Assn.品牌帽子，这些难忘的瞬间让粉丝们更贴近赛场激情。此外，活动参与者还首次体验了 U.S. Polo Assn. 的招牌鸡尾酒“The Divot Stomp”。这款特调饮品仅在 VIP 贵宾区供应，并于每日赛事标志性的中场休息环节呈献。特调饮品盛装于可重复使用的铝制杯中，并配有定制马球槌搅拌棒，为周末庆典增添了另一重互动元素，球迷们更将这些杯具带回家作为纪念品。为期三天的马球节也为U.S. Polo Assn.的全球马球衫宣传活动“源自赛场的经典”提供了绝佳舞台，彰显了该品牌最具辨识度的产品与其马球运动起源之间的真实联系。在整个活动现场，参与者一边探索受运动与时尚启发的全新季节系列，一边体验以标志性马球衫为核心的互动环节。“切斯特顿公园马球赛（Chestertons Polo in the Park）完美诠释了马球运动的独特魅力——集竞技、时尚、娱乐、亲民与社区精神于一体，且坐落于全球最具活力的城市之一的核心地带，”USPA Global总裁兼首席执行官J·迈克尔·普林斯表示。该公司负责管理和推广市值数十亿美元的U.S. Polo Assn.品牌。“作为源自马球运动的品牌，我们持续的合作让我们能够以真实的方式与消费者建立联系，同时颂扬定义了伦敦和马球运动的传统、活力与全球吸引力。”自2009年创办以来，“切斯特顿公园马球节”已发展成为全球规模最大的马球生活方式节庆活动之一，并始终是伦敦市中心唯一举办的马球赛事。2026年的赛事汇聚了六支代表全球城市与品牌的队伍，包括迪士尼+“Rivals”队、New Equity“伦敦”队、IBV Gold“开普敦”队——该队阵容中包含U.S. Polo Assn. 品牌大使尼科和卢卡斯·埃斯科巴；Kohn, Loeb & Co.苏黎世队；Icon Global/AMASE德克萨斯队；以及红海全球利雅得队。本届节日的每日主题包括：周五的“国际日”，英格兰队对阵南非队；周六的“女士日”；以及周日的“决赛日”和“家庭日”。在2026年切斯特顿“公园马球赛”决赛中，红海全球利雅得队与Icon Global/AMASE德克萨斯队展开激烈角逐，最终在最后一节结束时以4比4战平。经过一场激动人心的决胜局，红海全球利雅得队在切斯特顿“公园马球赛”上取得了三连冠，队友塞萨尔·克雷斯波荣膺最有价值球员。“作为U.S. Polo Assn.在英国的战略合作伙伴，‘切斯特顿公园马球赛’始终是展现我们品牌与马球运动之间真实联系的重要平台，”U.S. Polo Assn.在英国的授权合作伙伴Brand Machine Group首席执行官布·贾利尔表示。“本次活动完美诠释了消费者钟爱U.S. Polo Assn.的所有特质，包括品牌传承、时尚风格、亲民特质和趣味性，这让我们得以在这个最重要的全球市场之一与粉丝们直接互动。”英国仍是U.S. Polo Assn.的重要增长市场，该品牌正持续在该地区拓展零售渠道并扩大消费者覆盖范围。消费者可登录www.uspoloassn.co.uk浏览最新系列及运动风单品。在切斯特顿“公园马球赛”的拍照墙前，美丽的宾客们摆出各种姿势在美国马球协会（U.S. Polo Assn.）位于伦敦市中心的为期三天的马球生活方式节“切斯特顿公园马球节”（Chestertons Polo in the Park）上的商品帐篷图片来源：Spot Me关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美国马球协会（USPA）的官方运动品牌，该协会成立于1890年，是美国规模最大的马球俱乐部和马球运动员组织。U.S. Polo Assn. 业务规模达数十亿美元，通过全球1,200多家直营门店及数千个其他销售网点，向全球190多个国家的消费者提供男女及儿童服饰、配饰和鞋履。该品牌赞助了全球各大马球赛事，包括每年在棕榈滩的NPC举行的美国公开马球锦标赛®——这是美国最顶级的马球赛事。通过与美国ESPN、欧洲TNT和Eurosport、印度Star Sports以及中东BeIn Sports达成的历史性合作协议，由U.S. Polo Assn.赞助的数项世界顶级马球锦标赛现已实现电视转播，使这项激动人心的运动首次触达全球数百万体育迷。据《License Global》报道，U.S. Polo Assn. 近期被《今日美国》评为“最值得信赖的品牌”之一，并始终与NFL、PGA巡回赛及一级方程式赛车并列，被公认为全球顶尖体育授权商之一。此外，这个以运动为灵感来源的品牌因全球业务增长和体育内容而屡获国际奖项。凭借其作为全球品牌的巨大成功，U.S. Polo Assn. 不仅登上了《福布斯》、《财富》、《现代零售》和《GQ》等杂志，还出现在雅虎财经和彭博社等全球众多知名媒体上。如需了解更多信息，请访问 uspoloassnglobal.com 并关注 @uspoloassn。USPA Global 是美国马球协会（USPA）的子公司，负责管理价值数十亿美元的运动品牌 U.S. Polo Assn.。USPA Global 还管理其子公司 Global Polo，后者是全球马球运动内容的领导者。如需了解更多信息，请访问 globalpolo.com 或在 YouTube 上关注 Global Polo。关于Brand Machine Group (BMG)BMG 是时尚创新领域的国际领军企业，凭借四十余年的行业经验，已发展成为一家垂直整合制造商和全球授权专家。BMG 与公认的市场领导者合作，在设计、制造和交付优质产品的过程中保持无缝协作，同时秉承多元品牌组合的核心精神，业务涵盖时尚、运动、户外及家居用品领域，包括成人服饰、童装和配饰。BMG旗下品牌组合包括U.S. Polo Assn.、Penfield、New Balance Kids、Duchamp、Jack Wills、Flyers American Born、Lee Kids、Peckham Rye、Wrangler Kids、Juicy Couture、Franklin & Marshall、Elle Junior和Ben Sherman。BMG通过确保全球供应链的全面透明度，并遵循ETI基础准则，重申其对坚持可持续和道德商业实践的承诺。请访问 brandmachinegroup.com 并关注 @brandmachinegroup。如需预约，请联系 sales@brandmachinegroup.com关于Sportgate InternationalSportgate International 是一家国际活动管理与体育营销机构。该公司成立于 2015 年，目前拥有多项活动资源，并为需要赞助及活动专业知识的企业、奢侈品牌、世界级场馆、旅游局及版权方提供咨询服务。Sportgate International 拥有系列奢华活动，旨在助力全球顶尖品牌、知名企业和个人实现其企业或个人目标。公司还与全球多家备受瞩目的场馆合作，提供原创内容，助力客户与特定受众建立联系并开展营销活动。如需了解更多信息，请访问 sportgateint.com。如需了解更多信息，请联系：Stacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comShannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.com来源：U.S. Polo Assn. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to report assay results that extend Hat's gold-copper mineralization approximately 150m beyond the known resource envelope, opening a new exploration frontier the Company calls the Far East Zone. Drill holes H102-H108, completed during the Company's 2025 drill program at its 100%-owned Hat Project in northwestern British Columbia, also returned standout gold-enriched intervals including 8.0m grading 4.04 g/t Au and 112.0m grading 0.40 g/t Au.The 2025 drill program tested two distinct eastern areas of the Hat system, 233m apart. Holes H102-H105 add drill density and continuity data within and below the eastern side of the 2026 Preliminary Economic Assessment (PEA) pit shell, reinforcing the geological interpretation that underpins the Company's existing resource. Holes H106-H108 delivered the headline result: a new mineralized corridor, the Far East Zone, identified approximately 150m east of the current resource envelope, with elevated gold grades pointing toward a distinct and compelling geological target for future drilling.Drill holes H102-H108 were not completed in time to be incorporated into the Mineral Resource Estimate (MRE) with an effective date of February 4, 2026 or the PEA disclosed in March 2026. These assays do not constitute an updated MRE, mineral reserve estimate, pit optimization or economic analysis. The Company expects to evaluate the results in future mineral resource modelling and future engineering studies.CEO CommentFarshad Shirvani, President and CEO of Doubleview Gold Corp., commented: "These results demonstrate that the Hat Project continues to grow beyond the mineralized footprint used in our recently completed Mineral Resource Estimate and Preliminary Economic Assessment. The discovery of the Far East Zone approximately 150 metres beyond the current mineralization envelope, together with multiple broad mineralized intervals and significant gold enrichment, reinforces our belief that Hat remains substantially underexplored. Importantly, none of these holes were included in the February 2026 Mineral Resource Estimate or March 2026 PEA. We believe these results further highlight the scale potential of the Hat Project and provide compelling targets for future resource growth and engineering studies."HighlightsFar East Zone step-out: H106-H108 identify assay-supported mineralization approximately 150m east of the existing mineralization envelope. Follow-up drilling is required to determine geometry, continuity and extent.Two eastern data areas: the H102-H105 and H106-H108 platforms are approximately 233m apart. Figures 1 to 4 illustrate the separation between the East Zone and the Far East Zone.Gold-enriched intervals: H106-H108 show a higher gold contribution in several intervals, including 8.0m grading 4.04 g/t Au in H106 and 112.0m grading 0.40 g/t Au in H108.Resource confidence work: H102-H105 provide added drill density and continuity information for future geological modelling. The assays support future assessment of mineral resource classification. They do not, by themselves, establish a change in Measured, Indicated or Inferred mineral resource quantities or classifications.CuEq values exclude scandium oxide: reported Sc2O3 grades remain outside the CuEq calculation and are shown separately in Table 1.Selected Assay ResultsH102: 693.0m grading 0.20% CuEq,including 17.5m grading 1.25% CuEq.H103: 531.0m grading 0.20% CuEq,including 145.0m grading 0.40% CuEq and 26.1m grading 0.96% CuEq.H104: 259.0m grading 0.39% CuEq,including 142.0m grading 0.47% CuEq and23.0m grading 1.22% CuEq.H105: 427.1m grading 0.21% CuEq,including 71.2m grading 0.35% CuEq.H106: 444.0m grading 0.29% CuEq andan overlapping interval of 403.0m grading 0.31% CuEq,including 132.0m grading 0.51% CuEq,48.0m grading 1.00% CuEq,16.6m grading 2.02% CuEq and8.0m grading 3.93% CuEq.H107: 530.2m grading 0.20% CuEq andan overlapping interval of 463.0m grading 0.21% CuEq,including 22.2m grading 0.57% CuEq.H108: 135.0m grading 0.39% CuEq,including 112.0m grading 0.43% CuEq, anda separate interval of 75.0m grading 0.25% CuEq.All reported intervals are drill core lengths. True widths have not been determined. Complete assay intervals are presented in Table 1.Table 1: Summary of H102-H108 Drill Core Assay InterceptsDDHNoteFrom (m)To (m)Length (m)CuEq (%) not incl Sc2O3Au (g/t)Cu (%)Ag (g/t)Co (g/t)Sc2O3 (g/t)H102 6.0699.0693.00.200.090.100.145449.7H102incl.246.0699.0453.00.230.100.120.165554.1H102incl.252.0257.05.00.830.370.430.4120128.4H102incl.348.0696.0348.00.250.110.130.194753.9H102incl.348.0394.046.00.350.130.200.197862.1H102incl.527.0528.01.05.462.253.3011.0029228.5H102incl.681.5699.017.51.250.670.640.696044.1H103 9.0540.0531.00.200.100.090.156739.8H103incl.39.0119.080.00.290.200.090.305538.1H103incl.236.3532.0295.70.240.110.110.138140.9H103incl.387.0532.0145.00.400.190.200.218542.1H103incl.396.0540.0144.00.400.190.200.207842.2H103incl.399.0489.090.00.500.270.240.248146.2H103incl.406.5432.626.10.960.630.380.2510051H104 12.051.039.00.220.140.080.274737.3H104 425.0684.0259.00.390.160.230.316044H104incl.426.0568.0142.00.470.190.280.337338.9H104incl.460.0483.023.01.220.450.780.7611443.6H105 18.0445.1427.10.210.110.090.155647.3H105incl.187.0388.6201.60.260.110.140.166754.6H105incl.197.0268.271.20.350.160.180.258445.4H105incl.360.0388.628.60.450.220.240.165253.1H106 18.0462.0444.00.290.190.100.125342H106incl.105.0508.0403.00.310.200.120.135643.1H106incl.105.0372.0267.00.350.260.100.136240.4H106incl.105.0237.0132.00.510.450.090.165637.4H106incl.105.0153.048.01.000.980.120.296432.5H106incl.105.0121.616.62.022.050.190.487532.7H106incl.105.0113.08.03.934.040.340.8912427.4H107 6.8537.0530.20.200.100.090.125440.1H107incl.107.0570.0463.00.210.100.100.125941.2H107incl.107.0537.0430.00.230.110.110.126040.7H107incl.107.0167.060.00.350.310.060.115038.6H107incl.107.0129.222.20.570.540.080.175336.3H107incl.299.0528.0229.00.250.090.160.166442.7H107incl.299.0354.055.00.410.130.260.279547.5H107incl.471.0528.057.00.390.130.250.255949.7H108 15.0150.0135.00.390.350.060.204037.1H108incl.38.0150.0112.00.430.400.070.224238.2H108And501.0576.075.00.250.100.130.256236.9 Notes: 1 - Copper Equivalent (CuEq) currently does not include Scandium2 - The intervals presented in this table are not true widths. The true width of mineralized sections has not been determined.3 - Metal equivalents should not be relied upon for future evaluations. Drill hole intercepts included in this news release are core lengths that may or may not represent true widths of mineralization. It is not possible to determine true widths.4 - Parameters used to calculate Copper Equivalent: Au price (US$/oz): 2365.09; Ag price (US$/oz): 27.43; Cu price (US$/lb): 4.17; Co price (US$/lb): 14.76. Au recovery: 89.0%; Ag recovery: 68.0%; Cu recovery: 84.0%; Co recovery: 78.0%. * Copper Equivalent Calculation CuEq in % = ([Ag grade in ppm] *27.43*0.68/31.1035 + [Au grade in ppm] *2365.09*.89/31.1035 + 0.0001* [Co grade in ppm] *14.76*0.78*22.0462 + 0.0001* [Cu grade in ppm] *4.17*0.84*22.0462)/(4.17*22.0462*0.84).Details of the algorithm used to estimate %CuEq are presented in the notes above. The metal values used in our current algorithm are average trailing three years commodity prices, and do not reflect recent dramatic increases in prices of mineral commodities. Scandium, a high value strategic alloy metal (customarily quoted as Sc2O3 ) that is present in small but highly important amounts in Hat mineralization.Core samples are delivered securely to a fully accredited commercial laboratory and processed by industry-standard methods. Assays are received at irregular intervals, verified by reference to notes provided by our field crew, added to our database, and disseminated publicly by News Release.Figure 1: Plan view showing drill holes H102-H108 relative to the 2026 PEA pit shell and the eastern side of the Hat mineralized system.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_001full.jpgFigure 2: Cross-section through H102-H105 showing mineralized intervals within and below the eastern side of the 2026 PEA pit shell.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_002full.jpgFigure 3: Cross-section through H106-H108 showing the Far East Zone. The section illustrates a mineralized horizon extending more than 250m vertically in this view.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_003full.jpgGeological InterpretationResults from H102-H105 provide additional information on continuity within and below the eastern side of the PEA pit shell. Figure 2 shows reported intervals extending more than 150m below the shell in this section. The new data increase drill coverage in areas relevant to future resource modelling and future assessment of mineral resource classification.Results from H106-H108 identify the Far East Zone approximately 150m east of the existing mineralization envelope. The H106-H108 platform lies approximately 233m from the H102-H105 platform. Figure 3 illustrates the vertical extent of reported mineralization in the Far East Zone section. Additional drilling is required to determine the zone geometry, continuity and relationship to the broader Hat system.H106-H108 are also notable for gold-enriched intervals. H106 returned 48.0m grading 0.98 g/t Au, including 16.6m grading 2.05 g/t Au and 8.0m grading 4.04 g/t Au. H108 returned 112.0m grading 0.40 g/t Au. These results provide geological vectors for follow-up work. The significance of the metal distribution will be assessed through further drilling and modelling.Figure 4: Plan view of the 2026 PEA pit shell showing the East Zone and Far East Zone drill areas.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_004full.jpgFigure 5: Three-dimensional perspective view looking west showing the 2026 PEA pit shell and the eastern 2025 drill areas.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_005full.jpgFigure 6: Three-dimensional view looking west showing 2025 drill intercepts below the 2026 PEA pit shell.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_006full.jpgFigure 7: Three-dimensional view looking north showing eastern drill intercepts relative to the 2026 PEA pit shell.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_007full.jpgTable 2 summarizes coordinates of the recent drill holes.Table 2: Drill Hole Locations and OrientationsCoordinates are reported in NAD83 / UTM Zone 9N.DDH ID UTM-East (m)UTM-North (m)Elevation (m)Dip (°)Azimuth (°)Max-Depth (m)H1023482036453897972-88.470732H1033482036453897972-67.84135720H1043482036453897972-75.79167702H1053482036453897972-80.7230663H1063484186453987982-89.110651H1073484186453987982-75.51100651H1083484186453987982-75.06170648 Quality Assurance and Quality Control:Hat Project drill cores are processed at Doubleview's field camp where they are photographed, measured and logged by our technical staff and then divided using a diamond bladed saw. One half is placed in a stout bag to form the assay sample that is forwarded securely to the independent analytical lab. The remaining half core is stored on site where it is available for further examination and sampling. The assay cores are subject to a Chain of Custody routine as they are shipped from camp to a bonded carrier for delivery to the lab.All core samples are prepared and analyzed at AGAT Laboratories in Calgary, an independent ISO 17025 and ISO 9001 certified facility. Samples are dried, crushed to 70% passing 2 mm, split to obtain a 250 g representative portion, and pulverized to 85% passing 75 µm. Gold, platinum, and palladium are assayed by 30-50 g fire assay with ICP-OES finish. Multi-element analyses (up to 48 elements) are performed by four-acid digestion with ICP-OES/MS, with ore-grade assays applied where required. Selected samples are further analyzed for whole-rock oxides using lithium borate fusion with ICP-OES, and Loss on Ignition is determined separately. Routine quality assurance protocols include insertion of blanks, duplicates, and certified reference materials, ensuring accuracy and reliability of results.Doubleview maintains a website at www.doubleview.ca.Qualified Persons:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the technical contents of this news release. He is not independent of Doubleview as he is a shareholder in the company.About Doubleview Gold CorpDoubleview Gold Corp. is mineral resource exploration and development company headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX-Venture Exchange (TSXV: DBG), (OTCQB: DBLVF), (WKN: LA1W038), and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold Corp Vancouver, BC Farshad Shirvani President & CEO T: (604) 678-9587 E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Forward-Looking InformationCertain of the statements made and information contained herein may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements in this news release include, but are not limited to, statements regarding: the interpretation of drill results; the potential extension of mineralization; the identification and significance of the far east mineralized zone; the potential incorporation of drill holes H102 to H108 into future geological models, Mineral Resource Estimates, Preliminary Economic Assessments or other economic studies; the potential for future conversion of Mineral Resources into higher confidence categories; future drilling plans; future exploration programs; the potential economic significance of scandium, cobalt, copper, gold and silver mineralization; and the continued advancement of the Hat Project.Forward-looking statements are based on assumptions that management considers reasonable at the time they are made, including assumptions regarding geological continuity, future exploration results, metallurgical recoveries, metal prices, availability of financing, regulatory approvals, access to the property, and the Company's ability to complete future technical studies. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those projected. Such risks include, but are not limited to: risks associated with mineral exploration and development; uncertainty of geological interpretation; uncertainty of Mineral Resource estimation; volatility in metal prices; metallurgical and processing risks; permitting and environmental risks; title and access risks; financing risks; equipment availability; First Nations consultation and engagement; and other risks disclosed in the Company's public filings.Except as required by applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300676 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月9日 - (亚太商讯 via SeaPRwire.com) - 2026年6月9日，云顶新耀今日宣布与江苏威凯尔医药科技股份有限公司（以下简称"威凯尔"）达成独家授权许可协议，获得维卡格雷（Sumecigrel，曾用名：Vicagrel）在亚太多个国家与地区（东南亚、韩国、澳大利亚、中国香港、中国澳门及中国台湾地区）临床开发、注册和商业化的独家许可。根据协议，云顶新耀将向威凯尔医药支付人民币2,000万元的首付款，以及后续里程碑款和合作产品商业供货款项。此次合作不仅丰富了公司心血管产品组合，也体现了云顶新耀对亚太市场的高度重视，展示出持续推进区域战略、加速创新药价值实现的决心。维卡格雷属于抗血小板聚集药物，是一款全新一代口服P2Y12受体拮抗剂，临床开发用于治疗并预防急性冠脉综合征（ACS）、缺血性脑卒中（IS）以及外周动脉性疾病（PAD）等动脉粥样硬化血栓形成事件。该药物为威凯尔医药自研1类抗血栓新药，目前正在推进中、美、欧等多国新药上市许可申请（NDA）准备工作。维卡格雷药物设计思路旨在解决"氯吡格雷抵抗"黑框警告问题，首创优化氯吡格雷代谢路径的同时保留与氯吡格雷相同活性代谢物的分子发现路径，以期实现更平衡地掌握抗血小板药物疗效获益与出血风险的"双刃剑"，是一款起效更快、用量更低、疗效更稳定、出血风险更可控、代谢负担更小、应用场景更广泛的新型抗血小板药物，具备同类最佳（Best-in-Class）药物的潜力，未来有望能够更全面地满足日趋个体化的抗血栓治疗场景，成为抗血栓市场的重磅产品。据了解，心脑血管疾病为全球范围内的首要死亡原因之一，相关死亡人数显著上升至2019年的1,790万例，占当年全球总死亡人数的约32%。其中，约85%的死亡由心肌梗死（急性冠脉综合征的主要类型）及脑卒中所致。2023年心脑血管疾病导致死亡的例数进一步上升至1,920万人。抗血小板药物通过抑制血小板活化、黏附和聚集，从而降低血栓形成风险，主要用于动脉粥样硬化性血栓疾病的预防和治疗。其中，P2Y12受体拮抗剂是常见主要抗血小板药物，已上市包括氯吡格雷、替格瑞洛、普拉格雷。然而"氯吡格雷抵抗"、替格瑞洛与普拉格雷的"高出血风险"的黑框警告问题，使得抗血小板药物的疗效与出血风险始终未能实现更优的临床获益风险比。这一领域仍存在亟待满足的临床需求。云顶新耀董事会主席吴以芳表示："此次与威凯尔医药达成维卡格雷在亚太地区的授权合作是公司持续深化亚太战略布局的又一举措。维卡格雷是一款潜在同类最佳的新一代口服P2Y12受体拮抗剂，展现出差异化的临床优势，有望成为公司心血管产品组合的有益补充。云顶新耀将依托亚太地区丰富的临床开发经验、成熟的注册能力及本地化商业化能力，并发挥作为国际化创新药商业化平台的体系化优势，推动维卡格雷在相关市场释放临床价值和商业价值，实现双方优势的深度协同，为更多患者提供创新治疗选择。"威凯尔医药联合创始人、董事长、CEO龚彦春博士表示："维卡格雷作为公司研发的新型抗血栓药物，是我们首个布局的创新药产品。此次与云顶新耀达成战略合作，是维卡格雷全球商业化战略布局的第一步，也是源头创新药企与国际化商业平台的双向共赢。威凯尔医药以AI赋能差异化源头设计，持续专注于创新药物与领先疗法开发，是中国抗血小板领域原研创新赛道领跑者。我们将加速推进维卡格雷全球研发、注册进程，夯实产品全球竞争壁垒，为亚太地区乃至全球范围的心血管疾病诊疗贡献中国创新力量。"维卡格雷作为全新一代P2Y12受体拮抗剂，当前已完成I期、II期、中美PK/PD桥接以及III期等多项临床试验，并展现出具备充分临床价值的疗效与安全性，未来在有望成为急性冠脉综合征（ACS）、缺血性脑卒中（IS）以及外周动脉性疾病（PAD）患者更优的临床治疗方案。值得关注的是，维卡格雷的引入进一步丰富了云顶新耀在心血管疾病领域的产品组合。随着公司持续拓展CKM（心血管、肾脏及代谢）疾病领域布局，维卡格雷将进一步补充其在心血管领域的产品矩阵，并有望与现有产品及管线形成协同效应，进一步完善公司在相关治疗领域的布局深度。从战略层面来看，此次合作也是云顶新耀持续深化亚太布局的重要体现。据了解，近期公司围绕亚太市场持续推进战略合作与资源整合，与天广实达成合作，获得第三代CD20单抗倍捷欣(R)在亚太地区的商业化权益，进一步强化了肾科及自身免疫领域的产品组合。业内人士认为，此次维卡格雷授权延续了云顶新耀深耕亚太市场的发展思路，也反映出公司持续推动创新产品区域开发与商业化落地的战略方向。随着区域产品组合与运营能力的不断完善，云顶新耀有望进一步发挥其国际化创新药平台优势，加速创新成果在亚太市场的价值转化。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 9, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.This collaboration strengthens the Company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market.Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023.Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area.“This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest’s cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel’s development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients.”"As our novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel’s global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large."As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.Of note, the addition of Sumecigrel further enriches Everest Medicines’ cardiovascular portfolio. As the Company continues to expand its presence in the CKM (cardiovascular, kidney and metabolic) disease space, Sumecigrel is expected to strengthen its cardiovascular product portfolio and generate synergies with existing products and pipeline assets, further deepening the Company’s presence in related therapeutic areas.From a strategic perspective, this collaboration represents another important step in Everest Medicines’ ongoing efforts to deepen its presence across the Asia-Pacific region. Notably, the Company has continued to advance strategic partnerships and resource integration across the region. Through its collaboration with Mabworks, Everest secured the commercialization rights to Bejescin®, a third-generation anti-CD20 therapy, in multiple Asia-Pacific markets, further strengthening its portfolio in nephrology and autoimmune diseases. Industry observers believe that the licensing of Sumecigrel reflects Everest Medicines’ continued commitment to the Asia-Pacific market and its strategy of accelerating the regional development and commercialization of innovative therapies. As its regional product portfolio and operating capabilities continue to expand, Everest Medicines is well positioned to further leverage its integrated biopharmaceutical platform and accelerate the value realization of innovative therapies across the Asia-Pacific region. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

上海, 2026年6月9日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今日宣布，公司携全球首创葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin，商品名：华堂宁(R)，香港地区商品名：華領片(R), MYHOMSIS(R)）的一系列研究成果亮相第86届美国糖尿病协会（ADA）科学年会，以口头报告+壁报展示形式，多维度呈现了公司以代谢稳态技术平台为核心，在联合用药协同增效、大规模上市后真实世界证据、AI精准诊疗和个性化诊疗工具等关键领域的突破性进展，进一步支持了多格列艾汀从源头上修复血糖稳态的机制优势，提示了多格列艾汀在2型糖尿病（T2D）、代谢相关脂肪性肝病（MASLD）、肥胖、青少年发病型成人糖尿病2型 (MODY2)等复杂代谢性疾病领域的用药潜力，持续巩固了华领医药在全球血糖稳态研究领域的领先地位。一、依托代谢稳态平台，拓宽泛代谢疾病治疗布局多格列艾汀以"血糖传感器"葡萄糖激酶（GK）为核心靶点，通过修复2型糖尿病患者受损的GK功能和表达，提升T2D患者血糖调控器官的葡萄糖敏感性，实现胰腺-肝脏-肠道多器官协同调控，从而改善患者血糖稳态，为糖尿病及一系列代谢紊乱疾病提供了全新的治疗范式。基于这一独特机制，华领医药在本届ADA重点公布三项联合用药在代谢性疾病动物模型中的研究。结果显示，多格列艾汀与口服小分子GLP‑1受体激动剂、甲状腺激素受体激动剂（THR-β agonist）、泛PPAR激动剂（pan-PPAR agonist）等药物联用后可产生协同效应，有望在降糖之外实现减重、调脂、降尿酸、改善胰岛素敏感性等多重获益。其中，华领医药通过口头报告展示了多格列艾汀联合口服小分子GLP‑1受体激动剂orforglipron的临床前研究成果，该研究首次在动物模型中证实，GKA与口服小分子GLP‑1受体激动剂的协同作用，为稳态修复+肠促胰素激活的口服联合方案提供机制与数据支撑。不仅如此，研究结果提示，联合用药有望解决临床应用中影响GLP-1受体激动剂用药依从性的一大常见难题--胃肠道耐受性问题。该项研究采用hGLP‑1R转基因伴随饮食诱导肥胖（DIO）小鼠模型，模拟人类肥胖伴2型糖尿病的病理状态，经4周每日一次口服给药，系统评估了单药与联合治疗在血糖控制、胰岛素分泌、体重、血脂及安全性等方面的差异。在药物机制上，多格列艾汀可修复胰岛、肝脏、肠道的GK功能，重塑血糖稳态，提升葡萄糖刺激的胰岛素分泌（GSIS），促进内源性GLP‑1分泌；orforglipron则直接激活GLP-1受体，强效减重、降糖、改善血脂，但存在胃肠道不良反应风险。本次壁报展示的研究结果显示，联合治疗在以下方面存在协同效应：- 协同强效降糖：联合用药组呈现协同降糖效应，降糖效果显著优于单药，且具有减少两药用量的潜力（低剂量联用可达高剂量单药效果）；orforglipron还可放大多格列艾汀对β细胞功能与肝脏糖代谢的改善作用。- 显著提升β细胞功能：多格列艾汀改善DIO小鼠的β细胞功能，联合用药后胰岛素分泌功能与敏感性呈协同增益，实现更优血糖控制与β细胞保护。- 维持减重获益与血脂调节获益：联合用药组保留orforglipron的减重效果以及对于血脂的调节获益。- 安全性与耐受性：联合用药整体耐受良好，无新增不良信号；剂量节约可显著减少恶心、呕吐等GLP‑1类常见胃肠道反应，提升长期依从性。该研究提示，联合用药实现了降糖、减重、调脂三重协同，在显著降低空腹与餐后血糖的同时，可减少GLP‑1受体激动剂的用量，降低胃肠道不良反应，有望为2型糖尿病合并肥胖患者提供更高效、更耐受，且具备差异化优势的口服联合方案。未来，华领医药还将进一步开展临床研究，验证联合用药在人群中的疗效与安全性，探索最佳剂量配比与适用人群。华领医药还通过壁报展示了另外两项联合用药研究成果：1、在饮食诱导肥胖模型小鼠实验中，多格列艾汀与THR-β激动剂Resmetirom联合用药，在MASLD小鼠模型中，能够协同改善机体代谢状态、发挥肝脏保护作用，有效优化血糖管控、调节血脂水平、降低尿酸，减轻肝纤维化病变。此项研究结果表明，多格列艾汀与THR-β激动剂联合治疗方案，对MASLD和T2D具备良好的临床应用潜力。2、多格列艾汀与pan-PPAR激动剂 Chiglitazar联合使用，在MASLD合并肥胖糖尿病小鼠模型中，展现出显著的协同代谢获益，降糖疗效优于单药治疗，同时，可以优化基础糖代谢水平，提升葡萄糖刺激状态下的糖分代谢效率。该联合方案相比单药治疗可更有效改善小鼠糖耐量、降低胰岛素抵抗、提升胰岛素敏感性与 β 细胞功能，并升高高密度脂蛋白胆固醇水平，证实联用方案对MASLD相关代谢紊乱具有良好调控潜力，为后续开展临床研究、探索其在代谢及肝脏疾病领域的治疗价值提供了重要临床前支撑。上述研究共同验证了多格列艾汀凭借其恢复代谢稳态的核心优势，可以与多种靶点药物形成协同，有望持续拓宽在肥胖、MASLD等泛代谢疾病领域的治疗布局。二、大规模上市后真实世界研究支撑临床广泛应用本届ADA年会上，华领医药同时公布了大规模上市后真实世界研究"BLOOM研究"的更多核心数据，研究聚焦多格列艾汀在常规临床场景中的应用，旨在评估多格列艾汀在各类不同临床特征的广泛2型糖尿病患者中使用的长期安全性与疗效。BLOOM研究覆盖中国80家临床中心，共纳入2024例2型糖尿病患者（其中男性占62%，平均年龄55.5岁，平均BMI值 25.1，糖尿病病程7.9年，基线HbA1c为7.8%），随访周期长达52周，全面评估了多格列艾汀在真实临床场景中单药或联合其他降糖药治疗的长期安全性与有效性。研究人群高度贴近临床实际，涵盖不同年龄、病程、基线血糖水平、合并用药与并发症状态，包括老年患者、肾功能不全患者、联用包括胰岛素在内的多种降糖药的复杂患者，结果显示：- 52周治疗期内，无药物相关严重不良事件（SAE），无严重低血糖事件，有临床意义的低血糖发生率低于1%，与3期临床相比未观察到新的不良反应；- 经52周治疗，患者整体HbA1c较基线显著下降，血糖达标率（HbA1c